Ponta Wealth Partners LLC Buys New Holdings in Merck & Co., Inc. $MRK

Ponta Wealth Partners LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,342 shares of the company’s stock, valued at approximately $562,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Manske Wealth Management grew its holdings in Merck & Co., Inc. by 14.0% in the 4th quarter. Manske Wealth Management now owns 11,873 shares of the company’s stock worth $1,250,000 after acquiring an additional 1,461 shares during the last quarter. Total Investment Management Inc. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $205,000. Indivisible Partners purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $1,350,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Merck & Co., Inc. by 4.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,411,429 shares of the company’s stock worth $576,083,000 after purchasing an additional 238,477 shares during the period. Finally, AssuredPartners Investment Advisors LLC grew its stake in shares of Merck & Co., Inc. by 166.3% in the fourth quarter. AssuredPartners Investment Advisors LLC now owns 12,332 shares of the company’s stock worth $1,298,000 after purchasing an additional 7,701 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Activity

In other Merck & Co., Inc. news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider owned 21,197 shares of the company’s stock, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 189,258 shares of company stock valued at $22,663,993 over the last three months. Corporate insiders own 0.17% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst lifts Merck price target after Q1 beat — a recent note raised the target following Merck’s better-than-expected Q1 results, reinforcing upside potential and supporting investor sentiment. Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates
• Positive Sentiment: BMO Capital reiterates Buy — institutional support from BMO keeps conviction in Merck’s growth and pipeline prospects, which can bolster demand for the stock. BMO Capital Remains a Buy on Merck & Company (MRK)
• Positive Sentiment: Merck completes acquisition of Terns Pharmaceuticals — closing Terns adds oncology assets and near-term R&D value that could lift future revenue if assets progress. Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
• Positive Sentiment: Regulatory boost for Terns’ candidate — MSD/ Merck’s TERN-701 received FDA breakthrough therapy designation for Ph+ CML (non-T315I), enhancing the strategic value of the acquired pipeline. MSD concludes Terns acquisition to expand CML pipeline
• Neutral Sentiment: New coverage from Citigroup is Neutral with a $125 target — adds a fresh perspective but the rating is not bullish, leaving room for mixed investor reactions. Citigroup coverage note (summary)
• Neutral Sentiment: Analyst pieces highlight valuation debate after a pullback — some outlets argue Merck remains attractive on Keytruda growth and pipeline, while others point to conflicting valuation signals that could limit near-term gains. Is Merck (MRK) Still Attractive After Recent Pullback And Conflicting Valuation Signals
• Negative Sentiment: Shares slipped after the earnings report despite the beat — the market reaction suggests investors are cautious about near-term headwinds or valuation, which can pressure the stock in the short term. Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $113.53 on Thursday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.30. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a market capitalization of $280.39 billion, a PE ratio of 31.98, a PEG ratio of 2.24 and a beta of 0.18. The business has a fifty day moving average price of $117.31 and a 200-day moving average price of $108.12.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the company earned $2.22 EPS. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts expect that Merck & Co., Inc. will post 5.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MRK shares. Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a report on Thursday, January 8th. Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective on the stock. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. TD Cowen upped their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Finally, Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.